The Best of the Best in Big Pharma

Two of the world’s major listed drugmakers - AstraZeneca (AZN) and GSK (GSK) - both celebrated a strong start to 2023 and confirmed their forecasts for the rest of the year.

However, the two stocks are valued very differently by Wall Street. AstraZeneca shareholders are willing to pay 20 times forward earnings per share for 2023, while GSK’s shareholders are willing to pay a mere 10 times earnings.

These investors may be missing a huge opportunity. Last year, GSK completed its biggest restructuring in 20 years. It spun off its consumer health division Haleon (HLN), which sells over-the-counter medicines.

It is using the $8.78 billion bounty from the split to make acquisitions to fill its pipeline.

GSK’s vaccine division is the company’s star. It has developed the first ever vaccine for the common infection respiratory syncytial virus (RSV), which it believes presents a similar sized market opportunity to its shingles vaccine, which generated over $1 billion in sales in the first quarter alone. This vaccine was the first to ever be approved against RSV just a few days ago.

The company also has a leadership position in infectious diseases, which account for two-thirds of the drugs in its pipeline target.

Meanwhile, AstraZeneca has benefited from fortuitous timing, investing in oncology just as the science made great leaps forward over the past decade. The company then built on its success, so it now has a pipeline with drugs based on every current promising approach to cancer.

So, we have two very successful pharma giants. How do we pick which one to invest in? The quick and easy way to do this is to ask Magnifi to run the comparison for us. It’s as simple as asking Magnifi to “Compare AZN to GSK.”

Compare AZN to GSK

This is an example of a response using Magnifi. This image is not a recommendation or individual advice. Please see bottom disclaimer for additional information, including’s relationship with Magnifi.

As you can see, GSK is more volatile and has fallen in share price lately. AstraZeneca is the stronger stock on both counts.

This is just a starting point for further research, of course. With Magnifi, you can easily compare several stocks on more criteria, such as P/E ratio, margins, earnings, and much more.

Magnifi can also find competitors to these stocks, so you can see if there’s a similar-but-better stock out there. It’s as easy as typing in your question in your Magnifi account - click here to sign up.

This ability to have an investing AI pore over reams of data for you in seconds and spit out an easy-to-understand comparison of two or more stocks is an invaluable tool in deciding where to invest next.

We highly recommend you try it out. Click here to see how., a division of TIFIN Group LLC, is affiliated with Magnifi via common ownership. will receive cash compensation for referrals of clients who open accounts with Magnifi.

Magnifi LLC does not charge advisory fees or transaction fees for non-managed accounts. Clients who elect to have Magnifi LLC manage all or a portion of their account will be charged an advisory fee. Magnifi LLC receives compensation from product sponsors related to recommendations. Other fees and charges may apply.

Diversification does not guarantee a profit or protect against a loss in a declining market. It is a method used to help manage investment risk.

Mutual Funds and Exchange Traded Funds (ETFs) are sold by prospectus. Please consider the investment objectives, risks, charges, and expenses carefully before investing. The prospectus, which contains this and other information about the investment company, can be obtained from the Fund Company or your financial professional. Be sure to read the prospectus carefully before deciding whether to invest.

One thought on “The Best of the Best in Big Pharma

Comments are closed.